

KFIN/CERT13(3)/SEP/2022
October 10, 2022

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli
Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended September 30, 2022.

Dear Sir,


With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2022.

| Description of Complaint | Opening Balance as on 01.07.2022 | Received during the Period 01.07.2022 to 30.09.2022 | Attended/Resolved during the Period 01.07.2022 to 30.09.2022 | Pending as on 30.09.2022 |
|-----------------------------------|----------------------------------|---|--|--------------------------|
| Non-receipt of Dividend | NIL | 15 | 15 | NIL |
| Non-receipt of Annual reports | NIL | NIL | NIL | NIL |
| Non receipt of share certificates | NIL | 02 | 02 | NIL |
| SEBI | NIL | 04 | 04 | NIL |
| Stock Exchange | NIL | 04 | 04 | NIL |
| Total | NIL | 25 | 25 | NIL |

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Private Limited



Rajitha Cholleti
Asst. General Manager